Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 418

1.

Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era.

Gutierrez A, Bento L, Diaz-Lopez A, Barranco G, Garcia-Recio M, Lopez-Guillermo A, Dlouhy I, Rovira J, Rodriguez M, Sanchez Pina JM, Baile M, Martín A, Novelli S, Sancho JM, García O, Salar A, Bastos-Oreiro M, Rodriguez-Salazar MJ, Fernandez R, de la Cruz F, Queizan JA, González de Villambrosia S, Cordoba R, López A, Luzardo H, García D, Sastre-Serra J, Garcia JF, Montalban C, Cabanillas F, Rodríguez J.

Eur J Haematol. 2019 Dec 5. doi: 10.1111/ejh.13364. [Epub ahead of print]

PMID:
31804029
2.

A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev).

Cabanillas F, Rivera N, Acosta M, Pardo W, Solivan P, Rivera C, Liboy I.

Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):776-783. doi: 10.1016/j.clml.2019.07.002. Epub 2019 Jul 17.

PMID:
31591042
3.

Incidence and Risk Factors for Developing Herpes Zoster Among a Cohort of Patients Diagnosed With Lymphoma at a Community Cancer Center.

Goenaga Vázquez Y, Cabanillas F, Concepción JR, Díaz Miranda OL.

Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):e153-e158. doi: 10.1016/j.clml.2018.12.001. Epub 2018 Dec 19.

PMID:
30655095
4.

Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma.

Marrero WD, Cruz-Chacón A, Castillo C, Cabanillas F.

Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):e275-e277. doi: 10.1016/j.clml.2018.04.011. Epub 2018 May 4. No abstract available.

PMID:
29753690
5.

Mantle Cell Lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant?

Marrero WD, Cruz-Chacón A, Cabanillas F.

Leuk Lymphoma. 2018 Oct;59(10):2509-2511. doi: 10.1080/10428194.2018.1427863. Epub 2018 Feb 7. No abstract available.

PMID:
29415598
6.

Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma.

Cabanillas F, Shah B.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):783-796. doi: 10.1016/j.clml.2017.10.007. Epub 2017 Nov 7. Review.

PMID:
29126866
7.

Results of Upfront Therapy for Marginal Zone Lymphoma.

Ortega JL, Cabanillas F, Rivera N, Tirado-Gomez M, Hallman D, Pardo WI, Bruno M.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):879-883. doi: 10.1016/j.clml.2017.09.014. Epub 2017 Sep 23.

PMID:
29042174
8.

Check this checkpoint inhibitor in lymphoma.

Cabanillas F, Rivera N.

Blood. 2017 Jul 20;130(3):234-235. doi: 10.1182/blood-2017-05-786293. No abstract available.

PMID:
28729332
9.

Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.

Martin P, Chen Z, Cheson BD, Robinson KS, Williams M, Rajguru SA, Friedberg JW, van der Jagt RH, LaCasce AS, Joyce R, Ganjoo KN, Bartlett NL, Lemieux B, VanderWalde A, Herst J, Szer J, Bar MH, Cabanillas F, Dodds AJ, Montgomery PG, Pressnail B, Ellis T, Smith MR, Leonard JP.

Br J Haematol. 2017 Jul;178(2):250-256. doi: 10.1111/bjh.14667. Epub 2017 Apr 17.

10.

High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.

Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH.

Br J Haematol. 2017 Apr;177(2):263-270. doi: 10.1111/bjh.14541. Epub 2017 Mar 24.

11.

Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis.

Cabanillas F, Rivera N, Pardo WI.

Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):550-557. doi: 10.1016/j.clml.2016.08.011. Epub 2016 Aug 10. Review.

PMID:
27618361
12.

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.

Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A.

Br J Haematol. 2016 Oct;175(2):290-299. doi: 10.1111/bjh.14237. Epub 2016 Jul 22.

PMID:
27448187
13.

POEMS Syndrome: A Rare Disease With A Challenging Diagnosis.

Delgado Flores G, Robles Cartagena A, Robles Cartagena I, Muñiz A, Cabanillas F, Vicens R.

Bol Asoc Med P R. 2015 Jul-Sep;107(3):85-8.

PMID:
26742203
14.

Metastatic Ovarian Tumor Masquerading as Atypical Pneumonia.

Robles Cartagena I, Robles Cartagena A, Delgado Flores G, Monroig Quiles P, Cabanillas F, Báez L, Luis Acabá, Santos Reyes L, Vicens R.

Bol Asoc Med P R. 2015 Jul-Sep;107(3):38-41.

PMID:
26742194
15.

Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.

Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE.

Br J Haematol. 2016 Jan;172(1):80-8. doi: 10.1111/bjh.13796. Epub 2015 Dec 9.

16.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.

17.

Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.

Craig M, Hanna WT, Cabanillas F, Chen CS, Esseltine DL, Neuwirth R, O'Connor OA.

Br J Haematol. 2014 Sep;166(6):920-8. doi: 10.1111/bjh.12991. Epub 2014 Jul 9.

PMID:
25039282
18.

Clinical and pathological features of colorectal cancer in patients at a community hospital in Puerto Rico.

Cotto M, Rosado-Orozco KE, Rizek R, Fraguada LA, Brunet V, Cerra JJ, Sánchez A, Cabanillas F, Muñoz-Masso C, Tirado-Gómez M, Maldonado N.

P R Health Sci J. 2014 Jun;33(2):65-70.

PMID:
24964640
19.

Recent advances in the management of mantle cell lymphoma.

Rivera-Rodriguez N, Cabanillas F.

Curr Opin Oncol. 2013 Nov;25(6):716-21. doi: 10.1097/CCO.0000000000000010. Review.

PMID:
24076580
20.

Breast cancer molecular subtypes and survival in a hospital-based sample in Puerto Rico.

Ortiz AP, Frías O, Pérez J, Cabanillas F, Martínez L, Sánchez C, Capó-Ramos DE, González-Keelan C, Mora E, Suárez E.

Cancer Med. 2013 Jun;2(3):343-50. doi: 10.1002/cam4.78. Epub 2013 Apr 18.

21.

Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.

Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera J, Samaniego F, Silverman JA, Sarris A, Cabanillas F.

Br J Haematol. 2013 Sep;162(5):631-8. doi: 10.1111/bjh.12446. Epub 2013 Jun 27.

PMID:
23802738
22.

Reply to I.E. Haines.

Cabanillas F.

J Clin Oncol. 2013 May 10;31(14):1798. No abstract available.

PMID:
23802243
23.

Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm?

Cabanillas F.

J Clin Oncol. 2013 Jan 1;31(1):14-6. doi: 10.1200/JCO.2012.41.7527. Epub 2012 Oct 8. No abstract available.

PMID:
23045578
24.

Rectal adenocarcinoma: proposal for a model based on pretreatment prognostic factors.

Cabanillas F, Nieves-Plaza M, Quevedo G, Echenique IA.

P R Health Sci J. 2012 Jun;31(2):52-8.

25.

Triple negative breast cancer: a retrospective study of Hispanics residing in Puerto Rico.

Giraldo-Jiménez MY, Cabanillas F, Negrón V, Echenique M, Mojica P, Santiago K, Marcial V, Vaquer R, Carlo-Vargas V.

P R Health Sci J. 2012 Jun;31(2):45-51.

PMID:
22783695
26.

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.

Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J.

Lancet Oncol. 2012 Jul;13(7):716-23. doi: 10.1016/S1470-2045(12)70200-0. Epub 2012 Jun 6.

PMID:
22677155
27.

Pixantrone: a new agent for relapsed aggressive lymphomas.

Cabanillas F.

Lancet Oncol. 2012 Jul;13(7):654-6. doi: 10.1016/S1470-2045(12)70232-2. Epub 2012 May 30. No abstract available.

PMID:
22652184
28.

New developments in the field of diffuse large cell lymphoma.

Cabanillas F.

Hematology. 2012 Apr;17 Suppl 1:S98-100. doi: 10.1179/102453312X13336169156050.

PMID:
22507792
29.

Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.

Cabanillas F, Cotto M, Liboy I, Rivera E, Pavia OA, Bruno M.

Leuk Lymphoma. 2012 Oct;53(10):1929-33. doi: 10.3109/10428194.2012.679264. Epub 2012 Apr 23.

PMID:
22448918
30.

Non-Hodgkin's lymphoma: the old and the new.

Cabanillas F.

Clin Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1:S87-90. doi: 10.1016/j.clml.2011.03.029. Epub 2011 Apr 28. Review.

PMID:
22035756
31.

Rituximab in DLBCL: 6 years on.

Cabanillas F.

Lancet Oncol. 2011 Oct;12(11):984-5. doi: 10.1016/S1470-2045(11)70251-0. Epub 2011 Sep 21. No abstract available.

PMID:
21940215
32.

Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.

Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L.

Leuk Lymphoma. 2012 Jan;53(1):50-6. doi: 10.3109/10428194.2011.616611. Epub 2011 Oct 24.

33.

Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab.

Maldonado NI, Cabanillas F, Jaffe ES, Raffeld M, Lozada L.

J Clin Oncol. 2011 Aug 1;29(22):e658-60. doi: 10.1200/JCO.2011.34.8656. Epub 2011 Jun 6. No abstract available.

34.

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL.

Anticancer Res. 2011 Apr;31(4):1417-20.

PMID:
21508395
35.

How important is whole brain radiotherapy for treatment of primary CNS lymphoma?

Cabanillas F.

Lancet Oncol. 2010 Nov;11(11):1011-2. doi: 10.1016/S1470-2045(10)70234-5. Epub 2010 Oct 20. No abstract available.

PMID:
20970379
36.

Front-line management of diffuse large B cell lymphoma.

Cabanillas F.

Curr Opin Oncol. 2010 Nov;22(6):642-5. doi: 10.1097/CCO.0b013e32833ed848. Review.

PMID:
20811278
37.

Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast cancer patients in Puerto Rico.

Ortiz AP, Frías O, González-Keelan C, Suárez E, Capó D, Pérez J, Cabanillas F, Mora E.

P R Health Sci J. 2010 Sep;29(3):265-71.

38.

Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later?

Cabanillas F.

P R Health Sci J. 2010 Sep;29(3):215-7. Review.

PMID:
20799507
39.

Therapeutic concepts in mantle cell lymphoma.

Rodriguez J, Gutierrez A, Obrador-Hevia A, Fernandez de Mattos S, Cabanillas F.

Eur J Haematol. 2010 Nov;85(5):371-86. doi: 10.1111/j.1600-0609.2010.01515.x. Review.

PMID:
20727006
40.

Marginal zone lymphomas: factors that affect the final outcome.

Mazloom A, Medeiros LJ, McLaughlin PW, Reed V, Cabanillas FF, Fayad LE, Pro B, Gonzalez G, Iyengar P, Urbauer DL, Dabaja BS.

Cancer. 2010 Sep 15;116(18):4291-8. doi: 10.1002/cncr.25325.

41.

Epigenetic therapy of lymphoma using histone deacetylase inhibitors.

Cotto M, Cabanillas F, Tirado M, García MV, Pacheco E.

Clin Transl Oncol. 2010 Jun;12(6):401-9. doi: 10.1007/s12094-010-0527-3. Review.

PMID:
20534395
42.

Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.

Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M.

Br J Haematol. 2010 Jul;150(2):200-8. doi: 10.1111/j.1365-2141.2010.08228.x. Epub 2010 May 26. Review. Erratum in: Br J Haematol.n 2010 Oct;151(1):111.

PMID:
20528872
43.

A proposed approach for the selection of the proper surgical therapy to obtain an adequate margin of resection in locally advanced ultra-low rectal cancer after modern preoperative CRX management.

Echenique I, Cabanillas F, Texidor V, Cáceres J, Isenberg G, Claudio C, Ayala R, Madera F.

Bol Asoc Med P R. 2009 Apr-Jun;101(2):53-5. Review.

PMID:
19954103
44.

Diffuse large-cell lymphoma. Part II: management.

García-Pallas MV, Betancourt-García RD, Pacheco E, Castro J, Cabanillas F.

P R Health Sci J. 2009 Mar;28(1):12-7. Review. No abstract available.

PMID:
19266734
45.

Diffuse large-cell lymphoma. Part I: clinical features, histology and prognosis.

Betancourt-García RD, García-Pallas MV, Pacheco E, Castro J, Cabanillas F.

P R Health Sci J. 2009 Mar;28(1):5-11. Review. No abstract available.

PMID:
19266733
46.

Severe anemia of rapid onset in an inmunocompromised host.

Rivera Rodríguez E, Cabanillas F.

Bol Asoc Med P R. 2008 Jul-Sep;100(3):42-6.

PMID:
19227716
47.

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.

Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Fayad L, Wayne Saville M, Kwak LW.

Ann Oncol. 2009 Apr;20(4):709-14. doi: 10.1093/annonc/mdn692. Epub 2009 Jan 15.

48.

Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.

Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J.

Cancer. 2008 Nov 15;113(10):2734-41. doi: 10.1002/cncr.23880.

49.

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.

Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE.

Ann Oncol. 2008 Mar;19(3):553-9. Epub 2007 Dec 13.

50.

Dose dense CHOP: when more is not always better!

Cabanillas F.

Leuk Lymphoma. 2007 May;48(5):845-6. No abstract available.

PMID:
17487722

Supplemental Content

Loading ...
Support Center